Literature DB >> 7504655

Septic shock: pathogenesis and treatment.

L Castillo1, M Sanchez.   

Abstract

Septic shock is the host's inflammatory response to infection. There are multiple endogenous mediators responsible for the pathogenesis of septic shock. Cytokines, nitric oxide and prostaglandins are some of the major mediators. The term sepsis syndrome allows for an earlier diagnosis and treatment. Management of septic shock is focused in maintaining hemodynamic stability and an adequate oxygen delivery and utilization. Careful attention to each organ-system is of paramount importance to prevent complications and improve outcome. Experimental therapies to modulate the inflammatory response are promising.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7504655     DOI: 10.1007/bf02751198

Source DB:  PubMed          Journal:  Indian J Pediatr        ISSN: 0019-5456            Impact factor:   1.967


  46 in total

1.  Inhibition of NO synthesis in septic shock.

Authors:  R S Hotchkiss; I E Karl; J L Parker; H R Adams
Journal:  Lancet       Date:  1992-02-15       Impact factor: 79.321

Review 2.  Septic shock: pathogenesis.

Authors:  M P Glauser; G Zanetti; J D Baumgartner; J Cohen
Journal:  Lancet       Date:  1991-09-21       Impact factor: 79.321

3.  Effect of nitric oxide synthase inhibitors on hypotension in patients with septic shock.

Authors:  A Petros; D Bennett; P Vallance
Journal:  Lancet       Date:  1991 Dec 21-28       Impact factor: 79.321

4.  Amino acid alterations and encephalopathy in the sepsis syndrome.

Authors:  C L Sprung; F B Cerra; H R Freund; R M Schein; F N Konstantinides; E H Marcial; M Pena
Journal:  Crit Care Med       Date:  1991-06       Impact factor: 7.598

Review 5.  Cachectin: more than a tumor necrosis factor.

Authors:  B Beutler; A Cerami
Journal:  N Engl J Med       Date:  1987-02-12       Impact factor: 91.245

6.  Interleukin-1 receptor antagonist reduces mortality from endotoxin shock.

Authors:  K Ohlsson; P Björk; M Bergenfeldt; R Hageman; R C Thompson
Journal:  Nature       Date:  1990-12-06       Impact factor: 49.962

7.  Monoclonal antibody to tumor necrosis factor alpha attenuates cardiopulmonary dysfunction in porcine gram-negative sepsis.

Authors:  C J Walsh; H J Sugerman; P G Mullen; P D Carey; S K Leeper-Woodford; G J Jesmok; E F Ellis; A A Fowler
Journal:  Arch Surg       Date:  1992-02

8.  The cardiovascular response of normal humans to the administration of endotoxin.

Authors:  A F Suffredini; R E Fromm; M M Parker; M Brenner; J A Kovacs; R A Wesley; J E Parrillo
Journal:  N Engl J Med       Date:  1989-08-03       Impact factor: 91.245

9.  Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.

Authors:  E J Ziegler; C J Fisher; C L Sprung; R C Straube; J C Sadoff; G E Foulke; C H Wortel; M P Fink; R P Dellinger; N N Teng
Journal:  N Engl J Med       Date:  1991-02-14       Impact factor: 91.245

10.  Efficacy and safety of naloxone in septic shock.

Authors:  P Rock; H Silverman; D Plump; Z Kecala; P Smith; J R Michael; W Summer
Journal:  Crit Care Med       Date:  1985-01       Impact factor: 7.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.